Stuart Essig, Ph.D.

STUART M. ESSIG, Ph.D.,  is Integra’s chairman of the board of directors. He has been our chairman since January 2012 and a director since he joined Integra in 1997. Stuart served as our chief executive officer from 1997 through 2012 and our president from 1997 until 2010. From February 2024 to June 2025, Stuart served as the executive chairman of the board. Stuart also currently serves as managing director of Prettybrook Partners LLC, a family office focused on investing in medical technology companies. Prettybrook has approximately 25 active investments in a variety of companies, typically as a co-investor with institutional private equity.

During Stuart’s more than 25-year tenure with the company, Integra has grown revenues from approximately $15 million to over $1.5 billion and established itself as a global leader in neurological solutions and regenerative tissue technologies.

Before joining Integra, Stuart was managing director of the medical technology practice at Goldman, Sachs & Co. He had ten years of broad healthcare experience at Goldman Sachs, serving as a senior merger and acquisitions advisor to an extensive range of domestic and international medical technology, pharmaceutical and biotechnology clients.

Stuart has been a director on the boards of numerous public companies, ranging in size from several hundred million dollars to $50 billion in levered market capitalization, and has chaired audit, compensation, finance and nominating and governance committees, served as lead director, and participated in CEO succession processes.

In addition to Integra, Stuart currently serves on the Board of Directors of IDEXX Laboratories, Inc. (NASDAQ:IDXX) and on the Board of Managers of Availity, LLC, the nation’s largest real-time health information network.  He is also a venture partner at Wellington Partners Advisory AG, a venture capital firm. 

Stuart previously served on the Board of Directors of Orthofix (NASDAQ:OFIX) from 2023 to 2024, Seaspine Holdings (NASDAQ:SPNE), from 2015 to 2022, prior to its merger with Orthofix, and St. Jude Medical Corporation (NYSE:SJM) from 1999 to 2017, prior to its sale to Abbott Corporation. From 2013 until 2019 he served on the Board of Owens & Minor, Inc. (NYSE:OMI), from 2005 until 2008 he served on the Board of Zimmer Holdings, Inc. (NYSE:ZMH), and from 1998 to 2002, he served on the Board of Vital Signs, Inc. (NASDAQ:VITL). 

Stuart served as Chairman of the Board of venture backed Mission Bio Inc., a life sciences business delivering single-cell multiomics solutions for precision medicine, and as Executive Chairman and Lead Director of private-equity backed Breg, Inc., a provider of sports medicine products.

Stuart served as a senior advisor to TowerBrook Capital Partners, a senior advisor to Water Street Healthcare Partners, and as an executive-in-residence at Cardinal Partners.  He was a founding investor member of Tigerlabs, a Princeton-based business accelerator. He also served on the executive committee, nominating and governance committee, and as treasurer of AdvaMed, the Advanced Medical Technology Association.

Stuart is also involved in several non-profit charitable organizations, including from time to time serving on their boards.  From 2012 to 2018, he served on the Board of Directors of Trenton-area non-profit, Isles, Inc. and from 2006 to 2024 as a volunteer and fund raiser for the Children’s Brain Tumor Foundation. He serves on the Leadership Council of the Princeton University School of Engineering and Applied Sciences and previously served on the NACD Compensation Committee Chair Advisory Council.

Stuart received an A.B. degree and graduated with magna cum laude and Phi Beta Kappa honors from the School of Public and International Affairs at Princeton University. He completed his MBA and Ph.D. degrees in financial economics from the University of Chicago, Graduate School of Business.